|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2012: Estimated cancer incidence,
mortality and prevalence worldwide. 2012, http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
Accessed February 20, 2014
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
No authors listed. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. Non-small
Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Azzoli CG, Baker S Jr, Temin S, Pao W,
Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D,
Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith
TJ, Strawn JR, Trent D and Giaccone G; American Society of Clinical
Oncology. American Society of Clinical Oncology clinical practice
guideline update on chemotherapy for stage IV non-small-cell lung
cancer. J Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar
|
|
5
|
National Comprehensive Cancer Network.
Clinical practice guidelines in oncology: non-small cell lung
cancer, version 2. 2012, http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Accessed August 10, 2013
|
|
6
|
Socinski MA, Schell MJ, Peterman A, Bakri
K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M and
Kies MS: Phase III trial comparing a defined duration of therapy
versus continuous therapy followed by second-line therapy in
advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol.
20:1335–1343. 2002. View Article : Google Scholar
|
|
7
|
Azzoli CG, Temin S, Aliff T, Baker S Jr,
Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L,
Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ,
Strawn JR, Trent D and Giaccone G; American Society of Clinical
Oncology. 2011 focused update of 2009 American Society of Clinical
Oncology clinical practice guideline update on chemotherapy for
stage IV non-small-cell lung cancer. J Clin Oncol. 29:3825–3831.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brodowicz T, Krzakowski M, Zwitter M,
Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits
K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C,
Wagnerova M, Oskina N, Soldatenkova V, Zielinski C and Wenczl M;
Central European Cooperative Oncology Group CECOG. Cisplatin and
gemcitabine first-line chemotherapy followed by maintenance
gemcitabine or best supportive care in advanced non-small cell lung
cancer: a phase III trial. Lung Cancer. 52:155–163. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paz-Ares L, de Marinis F, Dediu M, Thomas
M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M,
Corral J, Melemed S, John W, Chouaki N, Zimmermann AH,
Visseren-Grul C and Gridelli C: Maintenance therapy with pemetrexed
plus best supportive care versus placebo plus best supportive care
after induction therapy with pemetrexed plus cisplatin for advanced
non-squamous non-small-cell lung cancer (PARAMOUNT): a
double-blind, phase 3, randomized controlled trial. Lancet Oncol.
13:247–255. 2012.
|
|
10
|
Pérol M, Chouaid C, Pérol D, Barlési F,
Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G,
Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F,
Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M and Milleron B:
Randomized, phase III study of gemcitabine or erlotinib maintenance
therapy versus observation, with predefined second-line treatment,
after cisplatin-gemcitabine induction chemotherapy in advanced
non-small-cell lung cancer. J Clin Oncol. 30:3516–3524. 2012.
|
|
11
|
Fidias PM, Dakhil SR, Lyss AP, Loesch DM,
Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J,
Obasaju CK, Marciniak M, Gill J and Schiller JH: Phase III study of
immediate compared with delayed docetaxel after front-line therapy
with gemcitabine plus carboplatin in advanced non-small-cell lung
cancer. J Clin Oncol. 27:591–598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ciuleanu T, Brodowicz T, Zielinski C, Kim
JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V,
Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson
P, John WJ, Krejcy K and Belani CP: Maintenance pemetrexed plus
best supportive care versus placebo plus best supportive care for
non-small-cell lung cancer: a randomized, double-blind, phase 3
study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cappuzzo F, Ciuleanu T, Stelmakh L,
Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W,
Melezínek I, Klingelschmitt G, Klughammer B and Giaccone G; SATURN
investigators. Erlotinib as maintenance treatment in advanced
non-small-cell lung cancer: a multicentre, randomised,
placebo-controlled phase 3 study. Lancet Oncol. 11:521–529. 2010.
View Article : Google Scholar
|
|
14
|
Takeda K, Hida T, Sato T, Ando M, Seto T,
Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J,
Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I,
Kurata T, Nakagawa K and Fukuoka M: Randomized phase III trial of
platinum-doublet chemotherapy followed by gefitinib compared with
continued platinum-doublet chemotherapy in Japanese patients with
advanced non-small-cell lung cancer: results of a west Japan
thoracic oncology group trial (WJTOG0203). J Clin Oncol.
28:753–760. 2010.
|
|
15
|
Zhang L, Ma S, Song X, Han B, Cheng Y,
Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang
X, Hayashi N and Wang M; INFORM investigators. Gefitinib versus
placebo as maintenance therapy in patients with locally advanced or
metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a
multicentre, double-blind randomized phase 3 trial. Lancet Oncol.
13:466–475. 2012. View Article : Google Scholar
|
|
16
|
Pfister DG, Johnson DH, Azzoli CG, Sause
W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT
and Somerfield MR; American Society of Clinical Oncology. American
Society of Clinical Oncology treatment of unresectable
non-small-cell lung cancer guideline: update 2003. J Clin Oncol.
22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cancer Therapy Evaluation Program. Common
Terminology Criteria for Adverse Events (CTCAE) Version 30. DCTD,
NCI, NIH, DHHS; 2006, http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
Accessed August 10, 2013
|
|
19
|
von Plessen C, Bergman B, Andresen O,
Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo
U and Sorenson S: Palliative chemotherapy beyond three courses
conveys no survival or consistent quality-of-life benefits in
advanced non-small-cell lung cancer. Br J Cancer. 95:966–973.
2006.PubMed/NCBI
|
|
20
|
Park JO, Kim SW, Ahn JS, Suh C, Lee JS,
Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn
MJ, Lee JS, Yun YH, Lee JW and Park K: Phase III trial of two
versus four additional cycles in patients who are nonprogressive
after two cycles of platinum-based chemotherapy in non small-cell
lung cancer. J Clin Oncol. 25:5233–5239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soon YY, Stockler MR, Askie LM and Boyer
MJ: Duration of chemotherapy for advanced non-small-cell lung
cancer: a systematic review and meta-analysis of randomized trials.
J Clin Oncol. 27:3277–3283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, Millward M and Belani CP: Randomized, multinational,
phase III study of docetaxel plus platinum combinations versus
vinorelbine plus cisplatin for advanced non-small-cell lung cancer:
the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003.
View Article : Google Scholar : PubMed/NCBI
|
